 CAMBRIDGE, Mass., May 13, 2021 PRNewswire -- Synlogic, Inc. Nasdaq: SYBX, a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the first quarter ended March 31, 2021, and provided an update on its clinical and preclinical programs. 